他汀与二甲双胍使用与接受恩扎卢胺治疗的去势抵抗性前列腺癌患者结局:AFFIRM、PREVAIL和PROSPER的荟萃分析
该事后回顾性分析纳入三项评估恩扎卢胺的随机双盲安慰剂对照III期研究(AFFIRM、PREVAIL、PROSPER)的患者数据,考察基线他汀与二甲双胍使用与影像学无进展生存(rPFS)、无转移生存(MFS)、毒性及总生存(OS)的关联。单项试验多变量分析中,AFFIRM和PROSPER的OS及rPFS/MFS未受他汀或二甲双胍显著影响;PREVAIL中OS受他汀显著影响(HR 0.72;95%CI 0.59-0.89),rPFS受二甲双胍显著影响(HR 0.48;95%CI 0.34-0.70)。汇总分析中,他汀使用与OS改善显著相关(AFFIRM+PREVAIL:HR 0.83;95%CI 0.72-0.96;三试验汇总:HR 0.75;95%CI 0.66-0.85),二甲双胍使用无此关联。
要点
- PREVAIL中他汀使用与OS显著相关(HR 0.72;95%CI 0.59-0.89),二甲双胍与rPFS显著相关(HR 0.48;95%CI 0.34-0.70)。
- 汇总分析中他汀使用与OS改善显著相关:AFFIRM+PREVAIL(HR 0.83;95%CI 0.72-0.96),三试验汇总(HR 0.75;95%CI 0.66-0.85)。
- 二甲双胍使用在汇总分析中与OS无显著关联;三项试验间他汀或二甲双胍与rPFS、MFS及OS的关联不一致。
核心结论
- 三项试验间他汀或二甲双胍使用与rPFS、MFS及OS的关联不一致。
- 三试验汇总及AFFIRM+PREVAIL汇总分析显示,他汀而非二甲双胍使用与恩扎卢胺治疗患者死亡风险降低显著相关。
- 作者认为需进一步开展前瞻性对照研究。
研究设计与样本
- 事后回顾性分析,纳入三项评估恩扎卢胺的随机双盲安慰剂对照III期研究(AFFIRM、PREVAIL、PROSPER)的去势抵抗性前列腺癌患者数据。
- 校正可用临床预后变量后,对AFFIRM与PREVAIL汇总数据、三试验汇总数据及各试验单独数据进行多变量分析。
- 评估基线他汀与二甲双胍使用与rPFS、MFS、毒性及OS的关联。
主要发现
- 单项试验多变量分析中,AFFIRM和PROSPER的OS及rPFS/MFS未受他汀或二甲双胍使用显著影响。
- PREVAIL中OS受他汀显著影响(HR 0.72;95%CI 0.59-0.89),rPFS受二甲双胍显著影响(HR 0.48;95%CI 0.34-0.70)。
- 汇总分析中他汀使用与OS改善显著相关:AFFIRM+PREVAIL(HR 0.83;95%CI 0.72-0.96),AFFIRM+PREVAIL+PROSPER(HR 0.75;95%CI 0.66-0.85)。
- 汇总分析中二甲双胍使用与OS无显著关联。
关键数值与推荐
- PREVAIL中他汀与OS:HR 0.72;95%CI 0.59-0.89。
- PREVAIL中二甲双胍与rPFS:HR 0.48;95%CI 0.34-0.70。
- AFFIRM+PREVAIL汇总中他汀与OS:HR 0.83;95%CI 0.72-0.96。
- AFFIRM+PREVAIL+PROSPER汇总中他汀与OS:HR 0.75;95%CI 0.66-0.85。
临床怎么用
- 原文未据此给出推荐。
局限性
- 本文为事后回顾性分析。
- 作者认为需进一步开展前瞻性对照研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Statins and metformin are commonly prescribed for patients, including those with prostate cancer. Preclinical and epidemiologic studies of each agent have suggested anti-cancer properties. METHODS: Patient data from three randomised, double-blind, placebo-controlled, phase III studies evaluating enzalutamide (AFFIRM, PREVAIL and PROSPER) in patients with castration-resistant prostate cancer were included in this analysis. This post hoc, retrospective study examined the association of statin and metformin on radiographic progression-free survival (rPFS), metastasis-free survival (MFS), toxicity and overall survival (OS). After adjusting for available clinical prognostic variables, multivariate analyses were performed on pooled data from AFFIRM and PREVAIL, all three trials pooled, and each trial individually, to assess differential efficacy in these end-points associated with the baseline use of these medications. RESULTS: In the multivariate analysis of the individual trials, OS and rPFS/MFS were not significantly influenced by statin or metformin use in AFFIRM or PROSPER. However, in PREVAIL, OS was significantly influenced by statin (hazard ratio [HR] 0.72; 95% confidence interval [CI] 0.59-0.89) and rPFS was significantly influenced by metformin (HR, 0.48; 95% CI 0.34-0.70). In pooled analyses, improved OS was significantly associated with statin use but not metformin use for AFFIRM+PREVAIL trials (HR 0.83; 95% CI 0.72-0.96) and AFFIRM+PREVAIL+PROSPER (HR 0.75; 95% CI 0.66-0.85). CONCLUSIONS: The association between statin or metformin use and rPFS, MFS and OS was inconsistent across three trials. Analyses of all three trials pooled and AFFIRM+PREVAIL pooled revealed that statin but not metformin use was significantly associated with a reduced risk of death in enzalutamide-treated patients. Additional prospective, controlled studies are warranted. CLINICAL TRIAL REGISTRATION: AFFIRM (NCT00974311), PREVAIL (NCT01212991) and PROSPER (NCT02003924).
引用
- Joshua AM, Armstrong A, Crumbaker M, et al. Statin and metformin use and outcomes in patients with castration-resistant prostate cancer treated with enzalutamide: A meta-analysis of AFFIRM, PREVAIL and PROSPER. Eur J Cancer. 2022. PMID: 35643841. doi:10.1016/j.ejca.2022.04.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。